WealthTrust Axiom LLC Sells 100 Shares of Eli Lilly and Company (NYSE:LLY)

WealthTrust Axiom LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 0.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,003 shares of the company’s stock after selling 100 shares during the quarter. Eli Lilly and makes up 1.1% of WealthTrust Axiom LLC’s portfolio, making the stock its 23rd largest position. WealthTrust Axiom LLC’s holdings in Eli Lilly and were worth $3,437,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Icapital Wealth LLC bought a new stake in Eli Lilly and during the 1st quarter worth about $28,000. AllSquare Wealth Management LLC bought a new stake in shares of Eli Lilly and in the 4th quarter valued at about $28,000. HWG Holdings LP bought a new stake in shares of Eli Lilly and in the 4th quarter valued at about $28,000. Leverty Financial Group LLC bought a new stake in shares of Eli Lilly and in the 4th quarter valued at about $29,000. Finally, FSB Premier Wealth Management Inc. bought a new stake in shares of Eli Lilly and in the 4th quarter valued at about $30,000. 82.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research analyst reports. SVB Leerink initiated coverage on shares of Eli Lilly and in a report on Monday, May 23rd. They issued an “outperform” rating and a $341.00 target price on the stock. Wells Fargo & Company upped their price target on shares of Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. Mizuho upped their price target on shares of Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. UBS Group upped their price target on shares of Eli Lilly and to $335.00 and gave the company an “outperform” rating in a research note on Wednesday, July 27th. Finally, JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. Three research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $316.06.

Eli Lilly and Price Performance

Shares of Eli Lilly and stock traded down $3.00 on Friday, reaching $302.79. 73,570 shares of the stock were exchanged, compared to its average volume of 2,376,201. The firm has a market cap of $287.70 billion, a PE ratio of 45.01, a P/E/G ratio of 2.22 and a beta of 0.35. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The firm’s 50 day moving average is $316.54 and its 200-day moving average is $288.64. Eli Lilly and Company has a one year low of $220.20 and a one year high of $335.33.

Eli Lilly and (NYSE:LLY – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.86 by ($0.61). The business had revenue of $6.49 billion for the quarter, compared to the consensus estimate of $6.85 billion. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. Eli Lilly and’s revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.87 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 8.34 EPS for the current fiscal year.

Eli Lilly and Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Shareholders of record on Monday, August 15th will be issued a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a yield of 1.29%. The ex-dividend date of this dividend is Friday, August 12th. Eli Lilly and’s payout ratio is 58.07%.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 700 shares of Eli Lilly and stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $302.00, for a total transaction of $211,400.00. Following the completion of the transaction, the insider now directly owns 105,472,666 shares in the company, valued at $31,852,745,132. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Eli Lilly and news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total value of $313,440.00. Following the sale, the chief accounting officer now owns 6,274 shares of the company’s stock, valued at $1,966,522.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 700 shares of Eli Lilly and stock in a transaction dated Wednesday, May 18th. The stock was sold at an average price of $302.00, for a total transaction of $211,400.00. Following the completion of the sale, the insider now directly owns 105,472,666 shares in the company, valued at approximately $31,852,745,132. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,195,396 shares of company stock worth $380,134,601. 0.12% of the stock is currently owned by company insiders.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.